AI Article Synopsis

  • The study aimed to compare two commercial tests for Hepatitis E virus (HEV) in HIV-positive patients and assess the chronicity of HEV in controlled HIV infections.
  • A total of 246 patients were tested, revealing that the Wantai assay identified more cases of anti-HEV antibodies compared to the MP assay, with none of the patients testing positive for HEV RNA.
  • Interestingly, about 25% of the HIV patients showed previous exposure to HEV, but the risk of developing chronic HEV infection was low among those on proper antiretroviral therapy, highlighting the variability in HEV test results across different assays.

Article Abstract

Objectives: Cases of chronic hepatitis E virus (HEV) infection have been described in HIV-infected patients. There are several commercial anti-HEV assays, but anti-HEV seroprevalence rates differ largely depending on the assay used. The aim of this study was to (1) compare two commercial anti-HEV assays in a German cohort of HIV-positive individuals, and (2) determine whether HEV takes chronic courses in controlled HIV infection.

Methods: 246 HIV patients were tested for both HEV RNA and HEV antibodies. All patients received antiretroviral therapy, if this was indicated, according to European guidelines. All but 19 individuals had CD4+ counts above 200/µl. Anti-HEV IgG was determined by two independent commercial assays (Wantai and MP).

Results: None of the patients tested HEV RNA positive. Anti-HEV IgG was detected more frequently by the Wantai assay (26%) than the MP assay (1.6%, p < 0.001). Patients born in Europe tested more frequently positive for anti-HEV (p = 0.047) than individuals from other regions. Increasing age but not CD4 count correlated with a higher likelihood of anti-HEV positivity (R = 0.313, p < 0.001).

Conclusions: About one quarter of HIV-infected patients show evidence of previous HEV contact. The risk of developing chronic HEV infection is very low in individuals receiving appropriate antiretroviral therapy. The large variability in HEV seroprevalence rates determined by different assays requires consideration for the diagnostic workup of HIV patients.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000441472DOI Listing

Publication Analysis

Top Keywords

hiv-infected patients
12
hepatitis virus
8
patients
8
commercial assays
8
hev
8
hev infection
8
commercial anti-hev
8
anti-hev assays
8
seroprevalence rates
8
hiv patients
8

Similar Publications

Background: Despite advancements in Human Immunodeficiency Virus (HIV) treatment and care, undernutrition remains a significant concern, accelerating disease progression and risk of Acquired Immune Deficiency Syndrome (AIDS)-related deaths. The nutritional status of second-line antiretroviral treatment (SLART) users in Ethiopia has not been thoroughly investigated. So, this study aimed to assess the nutritional status of HIV/AIDS patients who were on SLART and its associated factors in Northern Ethiopia.

View Article and Find Full Text PDF

Background: The Korean government is implementing policy to reduce medical costs and improve treatment related for human immunodeficiency virus (HIV) patients. The level of cost reduction and the benefits provided vary depending on how individuals with HIV utilize the system. This study aims to determine exact HIV prevalence by analyzing healthcare utilization patterns and examining differences in healthcare usage based on how individuals pay for their medical expenses.

View Article and Find Full Text PDF

Evaluation of bone mineral density and its influencing factors in patients infected with HIV under antiretroviral therapy.

BMC Infect Dis

January 2025

Department of Infectious Diseases, School of Medicine, Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Background: Reduced Bone Mineral Density (BMD) has been linked to Human Immunodeficiency Virus (HIV) infection and treatment. There is a lack of information regarding the osteoporosis status of middle-aged patients with HIV in Iran, despite the fact that Antiretroviral Therapy (ART) is widely accessible.

Objective: The purpose of this cross-sectional study was to assess the BMD status and low BMD risk factors in patients with HIV under ART living in Iran.

View Article and Find Full Text PDF

Objectives: This study aims to assess the correlation between clinical features and mortality in human immunodeficiency virus (HIV)-infected individuals with COVID-19.

Methods: A systematic literature search was conducted for cohort, cross-sectional, and case series that reported co-infection with HIV and COVID-19 published from January to September 2020. Clinical features such as age, comorbidities, CD4T lymphocyte counts, HIV RNA levels, and antiretroviral regimens were evaluated using meta-analyses and systematic reviews.

View Article and Find Full Text PDF

[Exploring the mechanism of HIV infection on T lymphocyte mitochondrial damage based on MAPK pathway].

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

December 2024

Department of Infection and Immunology, Changsha First Hospital, Changsha 410005, China.

Objective To clarify the mechanism that HIV infection mediates mitochondrial damage of CD4 T lymphocytes (CD4 T cells) through mitogen-activated protein kinase (MAPK) pathway. Methods From October 1st, 2022 to March 31st, 2023, 47 HIV-infected people who received antiretroviral therapy (ART) for 4 years were recruited, including 22 immune non-responders (INR) and 25 responders (IR); and 26 sex and age-matched control participants (HC) who were negative for HCV, HBV, and HIV infections. The immune parameters were analyzed by flow cytometry.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!